Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TKT May Have Enablement Argument Vs. Amgen's EPO Patents, Judge Says

Executive Summary

Transkaryotic Therapies may have an enablement argument against Amgen's patents for erythropoietin, Judge William Young said during a hearing held March 27-28 in Boston federal court to define claims included in the EPO marketer's patents.
Advertisement

Related Content

TKT Asks Judge To Limit Amgen's "30 Years" EPO Exclusivity As Trial Begins
TKT Asks Judge To Limit Amgen's "30 Years" EPO Exclusivity As Trial Begins
Amgen/TKT EPO
Amgen/TKT EPO
Advertisement
UsernamePublicRestriction

Register

PS035832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel